Literature DB >> 6653649

Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol.

J A Vedin, C Wilhelmsson, L Maass, L E Peterson.   

Abstract

The present study was done to establish the dose-response relationships for effects on heart rate and systolic and diastolic blood pressure, tolerance and plasma disappearance kinetics after large intravenous and oral doses of penbutolol. Twelve healthy volunteers were randomly allocated to receive penbutolol (n = 8) or placebo (n = 4) in this single blind, placebo-controlled investigation. The degree of beta-blockade was measured by standarized exercise tests at work loads selected to produce a heart rate of 150/min without treatment. Penbutolol was given as single i.v. doses of 3, 6 and 12 mg and as 40, 80 and 120 mg once daily for one week, measurements being made 2 and 24 h after the last dose. Penbutolol i.v. did not influence the resting heart rate but it did reduce resting systolic blood pressure in a non-dose dependent manner. Exercise heart rate and systolic pressure were lowered by all the intravenous doses. All oral doses of penbutolol lowered exercise heart rate and systolic blood pressure to the same extent. The reductions in exercise tachycardia was still present after 24 h. After i.v. administration t1/2 was approximately 1.2 h and the volume of distribution was 32-421. All doses were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653649     DOI: 10.1007/BF00542123

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  [Phenbutolol (Hoe 893d), a new highly efficient -sympatholytic agent with long action duration].

Authors:  G Härtfelder; H Lessenich; K Schmitt
Journal:  Arzneimittelforschung       Date:  1972-05

2.  Intrinsic sympathomimetic activity of penbutolol.

Authors:  G Nyberg; C Wilhelmsson; A Vedin
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

3.  [Beta adrenolytic activity and hemodynamic effects of penbutolol].

Authors:  J R Boissier; R Coutte; C Advenier; J F Giudicelli
Journal:  Therapie       Date:  1973 Nov-Dec       Impact factor: 2.070

4.  Physico-chemical and anlytical studies of penbutolol.

Authors:  P Hajdú; D Damm
Journal:  Arzneimittelforschung       Date:  1979

5.  Single and divided doses of penbutolol.

Authors:  F O Müller; H K Hundt; P A Bromley; J Torres; O Vanderbeke
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

6.  Duration of action of beta blockers.

Authors:  S R Johansson; M McCall; C Wilhelmsson; J A Vedin
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

  6 in total
  4 in total

1.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.

Authors:  A Wellstein; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.

Authors:  H Spahn; W Kirch; P Hajdu; E Mutschler; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.